- NVIDIA and Lilly will invest up to $1 billion over five years in an AI co-innovation lab.
- The lab will be based in the San Francisco Bay Area, starting early this year.
- The initiative will use NVIDIA BioNeMo and Vera Rubin architecture for drug discovery.
- Focus areas include AI-assisted experimentation, robotics, and digital twins for manufacturing.
Investment and Collaboration
NVIDIA and Eli Lilly are launching an AI co-innovation lab, investing up to $1 billion over five years. The lab will be located in the San Francisco Bay Area and aims to address challenges in drug discovery by combining Lilly's expertise in medicine with NVIDIA's AI capabilities.
Technological Framework
The lab will utilize NVIDIA's BioNeMo platform and Vera Rubin architecture to accelerate drug discovery. By integrating AI, robotics, and physical AI, the initiative seeks to enhance medicine development and production.
Continuous Learning System
The collaboration will focus on creating a continuous learning system that connects Lilly's wet labs with computational dry labs. This system will enable 24/7 AI-assisted experimentation, allowing for continuous improvement in experiments, data generation, and AI model development.
Broader Applications
Beyond drug discovery, the partnership will explore AI applications in clinical development, manufacturing, and commercial operations. The use of digital twins and NVIDIA's Omniverse libraries will help optimize supply chains and manufacturing processes.
